Involvement of EGF signalling in the pathogenesis of bone metastasis was implicated by the unexpected relief of bone pain in phase II clinical trials of EGFR inhibitor gefitinib in breast cancer patients (Albain et al, 2002; von Minckwitz et al, 2005). Here, EGF is linked to breast cancer.